Xin Lang Cai Jing·2026-02-03 18:42Fund Overview - The fund is named Huatai-PB Hang Seng Biotechnology Exchange-Traded Fund (ETF) and is a stock index investment fund [17][20] - The fund is managed by Huatai-PB Fund Management Co., Ltd. and the custodian is CITIC Jianzhong Securities Co., Ltd. [3][44] - The fund's initial offering period is from February 24, 2026, to March 4, 2026 [23] Subscription Details - The maximum fundraising limit for the fund is set at 2 billion RMB, excluding interest and subscription fees [4] - Investors can subscribe through online cash subscription or offline cash subscription methods, with specific dates for each [5][6] - The fund is open to individual investors, institutional investors, qualified foreign investors, and other investors permitted by laws and regulations [18] Subscription Process - For online subscriptions, investors must have a Shanghai Stock Exchange A-share account or a fund account [28] - The minimum subscription amount for online subscriptions is 1,000 shares or its multiples, while offline subscriptions require a minimum of 50,000 shares [9][27] - Subscription fees will be borne by investors, with specific rates applicable depending on the subscription method [24][25] Fund Management and Operations - The fund will be managed according to the "Fund Law," "Fund Contract," and other relevant regulations [16] - The fund's contract will become effective once it meets the registration conditions set by the China Securities Regulatory Commission (CSRC) [42][43] - The fund will be subject to various risks associated with stock market investments, including market risk and management risk [12][14]